[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fiPgNpq1_9hQiepxyHK_tVJRMv-vR9yS5J-_70L0tCRI":8,"$ft4_yGEoqZPNYY_aoay3xHRWArLp545Vcb64t6KT7F7s":55,"$fca_5Pzlwl6LSkO4e29irCrKCx2kThA__et_QVVS35qU":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},67006,867297,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","祁志勇","聊城市第二人民医院","甲状腺乳腺外科","住院医师",178,0,"乳腺癌 Her-2 阳性型治疗：了解曲妥珠单抗的关键知识","","https://ystcdn.venuertc.com/venue/AI/342688b9-29da-4660-bc02-2a47ad46e763.jpg","\u003Cdiv id=\"material_title\" class=\"breast-her2-title\">\n  乳腺癌 Her-2 阳性型治疗：了解曲妥珠单抗的关键知识\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#f6fafc 0%,#e2f0fb 100%);\">01 什么是Her-2阳性乳腺癌？基础认知\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗（Trastuzumab）是用于治疗Her-2阳性类型乳腺肿瘤的靶向药物。说起来，这类药品通过针对乳腺细胞表面的Her-2蛋白发挥疗效，用途十分明确。接下来，咱们要从7个关键用药细节切入，帮你理解安全使用曲妥珠单抗需要掌握的全部要点。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#fcf9f6 0%,#fbefe2 100%);\">02 曲妥珠单抗的成分、剂型与规格\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗属于重组人源化单克隆抗体。常见剂型为注射用冻干粉剂，规格多为150mg/瓶或420mg/瓶。每瓶需用专用注射用水溶解后静脉输注。\u003Cbr>\n    正确做法：配药由专业护士在严格无菌下完成，一般不建议家庭自备溶解和输注工具。实际使用中，每3周注射一次为主流方案，但给药频率和剂量，必须个体化安排。\u003Cbr>\n    临床上，曾有一位71岁女性患者在术后联合化疗期间应用曲妥珠单抗，每次注射前均进行药物溶解与配伍安全核查，确保剂量准确。\u003Cbr>\n    需要注意：不要更换药液稀释剂或随意延长配制时间，以免影响药效或增加污染风险。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#f6fcfa 0%,#e2fbe7 100%);\">03 曲妥珠单抗的作用机制 🚀\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    药理作用方面，曲妥珠单抗主要通过选择性结合Her-2（人表皮生长因子受体-2）蛋白，阻断肿瘤细胞的异常生长信号，并诱导体内免疫细胞直接杀灭表达Her-2的异常细胞。\u003Cbr>\n    临床研究表明，结合Her-2后，生长信号传递被切断，异常细胞生长受到抑制（Swain SM, Baselga J, Kim SB, et al., The New England Journal of Medicine, 2015）。\u003Cbr>\n    需要记住的是：药理机制决定了药物靶向性强，但也会涉及Her-2依赖细胞对药物敏感性的个体差异。因此，治疗前通常需要专业检测确认Her-2状态。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#fcf6fb 0%,#fbe2f9 100%);\">04 曲妥珠单抗的正确用法用量 ⏳\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗通过静脉滴注方式使用，首次剂量通常按8 mg/kg体重，后续按6 mg/kg体重每3周一次。每次输注应在医院内专业操作，初次输注时间不少于90分钟，后续不少于30分钟。滴速调整需根据患者耐受情况灵活掌握。\u003Cbr>\n    正确做法：严格按说明书方案及医嘱用药，绝不可自作主张缩短输注时间或更改间隔周期。\u003Cbr>\n    间断用药可能影响疗效，漏用时应尽早补用，并咨询医生方案调整。\u003Cbr>\n    有临床案例显示：患者因外出而错过输注一周后，返院由医生评估后重启治疗，并无明显不良影响，但建议一定要保持规则随访，防止长期延误。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#f6fcfa 0%,#e2fbf5 100%);\">05 药物相互作用需要警惕 🧬\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗与部分化疗药物如多西他赛（docetaxel）、紫杉醇（paclitaxel）等常联合使用，其相互作用机制复杂，涉及药物代谢、毒性叠加等方面。例如，与蒽环类化疗药物并用会增加心脏毒性风险。\u003Cbr>\n    正确做法：用药期间主动告知医生自身全部处方药、非处方药和保健品的使用状况。\u003Cbr>\n    需要间隔用药时听从专业指导，严禁自行添加新的药品。避免与活疫苗共同使用，治疗期间一般不建议接种活病毒疫苗。\u003Cbr>\n    说明书提示：合用紫杉类药物不会直接影响曲妥珠单抗的血药浓度，但合并用药需监测副作用。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#fcfef6 0%,#f9fbe2 100%);\">06 特殊人群用药调整\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗对不同人群有特别用药要求。\u003Cbr>\n    \u003Cb>老年人：\u003C/b>耐药性较弱，需特别关注心脏功能，可适当降低起始剂量并密切随访心脏超声。\u003Cbr>\n    \u003Cb>孕妇及哺乳期：\u003C/b>药品禁用于孕妇和哺乳期女性。有研究表明，动物实验中存在胚胎毒性，育龄女性使用期间必须采取可靠避孕措施（Genentech, Herceptin Prescribing Information, 2022）。\u003Cbr>\n    \u003Cb>肝肾功能减退者：\u003C/b>目前数据未显示需特殊剂量调整，但建议谨慎使用，必要时进行药物血药浓度及功能监测。\u003Cbr>\n    临床实践中，有位老年患者应用曲妥珠单抗期间，定期随访心脏彩超，发现心功能轻度下降后及时调整方案，保障了治疗安全。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#faf6fc 0%,#e6e2fb 100%);\">07 常见不良反应与应对方法💡\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗常见副作用包括输注反应（如发热、寒战）、乏力、恶心、皮疹、关节痛等。\u003Cbr>\n    数据显示，约30%-40%的患者首次输注时可出现轻度输注反应（Slamon DJ et al., The New England Journal of Medicine, 2001）。一般可在医生指导下停止或减慢滴速，或加用解热镇痛药改善。\u003Cbr>\n    \u003Cb>严重不良反应：\u003C/b>如心脏功能受损（左心室射血分数下降）、过敏反应、肺不良反应等，则须立即就医，必要时停用药物。出现呼吸困难、心悸、水肿等症状需立刻反馈给主管医生。\u003Cbr>\n    不要随意自行停药或断药，所有副作用都要与专业医生沟通确定处理方式。\u003Cbr>\n    案例经验：实际中患者在第一周期输注曲妥珠单抗时曾短暂低热，及时与护士沟通后延缓滴速，当次治疗顺利完成未留后遗症。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#f6fcfa 0%,#e4fbe2 100%);\">08 储存、运输与有效期管理\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗原粉须存放在2℃～8℃冰箱中，避免冷冻。配制好的溶液应尽快使用。开瓶后超过6小时未用的药液不得再用，避免药物变质失效。\u003Cbr>\n    正确做法：运输、存放过程中全程冷链管理，家庭提前备药时确保有独立冷藏设备。定期自查药品有效期，过期药不得再用，交医务人员妥善处理。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#fffbe6 0%,#fcfae2 100%);\">09 漏服和过量用药的处理办法\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    曲妥珠单抗如果漏服，建议尽快补用，并与医生沟通，确定下一次给药时间。绝不可擅自加量补药，以免出现超剂量反应。\u003Cbr>\n    过量使用可能导致严重输注反应、心功能损害等急性不良反应。一旦发生，请迅速就医，接受专业监测及处理。\u003Cbr>\n    需要注意：无论是少打还是多打，都不建议自行处理，一定要让专业医务人员帮忙制定补救方法。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#e6f2fb 0%,#f6f7fc 100%);\">10 治疗后的保健与随访建议\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    \u003Cb>定期复查：\u003C/b>用药期间和药后，必须严格按照医护人员安排做心脏超声、肝肾功能、血常规等指标复检，便于及时发现不良反应或调整治疗计划。\u003Cbr>\n    \u003Cb>健康管理：\u003C/b>建议保持营养均衡饮食、适当运动、保证充足休息。曲妥珠单抗不与饮食直接相互作用，但避免过多饮酒和滥用补品。\u003Cbr>\n    \u003Cb>疫苗接种：\u003C/b>治疗期间避免接种活疫苗，有注射需求请提前报告主管医生。\u003Cbr>\n    \u003Cb>告知与随访：\u003C/b>每次复查时需将全部用药历史与症状如实告知医生，便于专业团队全面评估。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#f2eee6 0%,#f7f6fb 100%);\">\u003Cspan style=\"font-size:1.2em;\">结语✍️：曲妥珠单抗用药关键回顾\u003C/span>\u003C/div>\n  \u003Cdiv class=\"breast-her2-text\">\n    总结来说，曲妥珠单抗以其独特、精准的机制为特定类型乳腺肿瘤提供了有效且相对安全的治疗方案。但它的使用细节很多，像准确计量、规则输注、密切监测心脏功能等缺一不可。漏用或过用、随意更改给药间隔、忽视复查都将加大药物风险。\u003Cbr>\n    再次提醒：用药每一步均需听从专业医务人员指导，发现任何不适及时反馈。只有严格执行这些安全细节，才能更好地发挥曲妥珠单抗的效果，减少副作用，保障用药安全。如果有疑问或出现异常，随时找主治医生咨询是最稳妥的做法。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"breast-her2-section breast-her2-citations\">\n  \u003Cdiv class=\"breast-her2-subtitle\" style=\"background:linear-gradient(90deg,#f5f5f5 0%,#e6ecf7 100%);\">\u003Cspan style=\"font-size:1.1em;\">参考文献\u003C/span>\u003C/div>\n  \u003Cul class=\"breast-her2-text\">\n    \u003Cli>Swain SM, Baselga J, Kim SB, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. \u003Ci>New England Journal of Medicine\u003C/i>. 2015;372(8):724-734.\u003C/li>\n    \u003Cli>Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. \u003Ci>New England Journal of Medicine\u003C/i>. 2001;344(11):783-792.\u003C/li>\n    \u003Cli>Genentech Inc. Herceptin (trastuzumab) [Prescribing Information]. 2022. South San Francisco, CA: Genentech, Inc.\u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003Cstyle>\n.breast-her2-title {\n  font-size: 2.3em;\n  font-weight: bold;\n  color: #2a4258;\n  margin: 40px 0 32px 0;\n  letter-spacing: 2px;\n  text-align: center;\n  line-height: 1.3;\n}\n.breast-her2-section {\n  margin: 32px auto 24px auto;\n  padding: 0 8%;\n  max-width: 980px;\n}\n.breast-her2-subtitle {\n  font-size: 1.33em;\n  font-weight: 600;\n  color: #14547e;\n  padding: 18px 28px;\n  border-radius: 16px;\n  margin-bottom: 18px;\n  background-repeat: no-repeat;\n  background-size: cover;\n  letter-spacing: 1px;\n  box-shadow: 0 2px 6px rgba(43,74,101,0.06);\n}\n.breast-her2-text {\n  background: #fff;\n  line-height: 1.9;\n  font-size: 1.08em;\n  color: #243344;\n  padding: 22px 28px 18px 28px;\n  border-radius: 12px;\n  box-shadow: 0 0px 6px rgba(87,108,134,0.09);\n  margin-bottom: 23px;\n}\n.breast-her2-text b {\n  color: #12507a;\n}\n.breast-her2-text ul {\n  margin-left: 26px;\n  padding-left: 0;\n}\n.breast-her2-citations {\n  margin-bottom: 70px;\n}\n.breast-her2-citations ul {\n  list-style-type: decimal;\n  font-size: 1em;\n}\n@media only screen and (max-width: 900px) {\n  .breast-her2-title { font-size: 1.5em; }\n  .breast-her2-section { padding: 0 2%; }\n  .breast-her2-subtitle { font-size: 1.08em; padding: 11px 13px;}\n  .breast-her2-text { font-size: 0.98em; padding: 12px 10px 12px 13px;}\n}\n\u003C/style>\n\n","\u003Cdiv id=\"material_title\" class=\"breast-her2-title\">\n  乳腺癌 Her-2 阳性型治疗：了解曲妥珠单抗的关键知识\n\u003C/div>\n\n\u003Cdiv clas",575,"2025-09-23 14:00:24","曲妥珠单抗, Her-2阳性乳腺癌, 乳腺癌治疗, 药物相互作用, 不良反应, 用药指导, 健康管理, 医学资讯","本文深入解析曲妥珠单抗在治疗Her-2阳性乳腺癌中的应用，确保患者了解用药细节、安全措施和不良反应，帮助提升治疗效果。","2025-10-02 21:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]